Skip to main content
. Author manuscript; available in PMC: 2016 May 20.
Published in final edited form as: J Urol. 2012 Nov 19;189(1):352–358. doi: 10.1016/j.juro.2012.08.190

Figure 1.

Figure 1

Group mean content of dynorphin in the lumbosacral and thoracolumbar spinal cord and serum. Panel A: Dynorphin content was significantly increased in the lumbosacral spinal cord of groups ZA and ZZ compared to groups AA and AZ (*p≤0.001; n=5-8/group). Panel B: Dynorphin content in the thoracolumbar spinal cord was not significantly altered by the treatments (n=6-8/group). Panel C: Dynorphin content in the thoracolumbar spinal cord of AA controls was significantly greater than in the lumbosacral spinal cord (p=0.006). Panel D: Dynorphin content in serum was not altered by the treatments (n=14-16/group). AA control data are shown in open bars.